

# Muhammad Ilmawan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6921796/publications.pdf>

Version: 2024-02-01

20  
papers

498  
citations

1305906

8  
h-index

939365

18  
g-index

22  
all docs

22  
docs citations

22  
times ranked

715  
citing authors

#	ARTICLE	IF	CITATIONS
1	The 8q24 Rs10090154c>T Gene Variant and Its Association with the Risk of Prostate Cancer: A Systematic Review and Meta-analysis. <i>Turkiye Klinikleri Journal of Medical Sciences</i> , 2021, 41, 166-175.	0.1	0
2	Anosmia and dysgeusia in SARS-CoV-2 infection: incidence and effects on COVID-19 severity and mortality, and the possible pathobiology mechanisms - a systematic review and meta-analysis. <i>F1000Research</i> , 2021, 10, 40.	0.8	85
3	Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis. <i>F1000Research</i> , 2021, 10, 64.	0.8	5
4	Global prevalence of prolonged gastrointestinal symptoms in COVID-19 survivors and potential pathogenesis: A systematic review and meta-analysis. <i>F1000Research</i> , 2021, 10, 301.	0.8	54
5	Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis. <i>F1000Research</i> , 2021, 10, 64.	0.8	7
6	The role of single nucleotide polymorphisms of IL-1A -889C>T (rs1800587), TNF-A -238G>A (rs361525), and VDR TaqI (rs731236) on susceptibility to herniated nucleus pulposus: a systematic review and meta-analysis. <i>F1000Research</i> , 2021, 10, 419.	0.8	1
7	Hemorrhagic and ischemic stroke in patients with coronavirus disease 2019: incidence, risk factors, and pathogenesis - a systematic review and meta-analysis. <i>F1000Research</i> , 2021, 10, 34.	0.8	41
8	Global prevalence of persistent neuromuscular symptoms and the possible pathomechanisms in COVID-19 recovered individuals: A systematic review and meta-analysis. <i>Narra J</i> , 2021, 1, .	1.7	26
9	The association between therapeutic plasma exchange and the risk of mortality among patients critically ill with COVID-19: a meta-analysis. <i>F1000Research</i> , 2021, 10, 1280.	0.8	4
10	Predictors of COVID-19 severity: a systematic review and meta-analysis. <i>F1000Research</i> , 2020, 9, 1107.	0.8	105
11	Nitride oxide synthase 3 and klotho gene polymorphisms in the pathogenesis of chronic kidney disease and age-related cognitive impairment: a systematic review and meta-analysis. <i>F1000Research</i> , 2020, 9, 252.	0.8	1
12	Global prevalence and pathogenesis of headache in COVID-19: A systematic review and meta-analysis. <i>F1000Research</i> , 2020, 9, 1316.	0.8	19
13	Comparison of major bleeding in patients with acute coronary syndrome that underwent coronary artery bypass grafting treated with clopidogrel or ticagrelor: a systematic review and meta-analysis. <i>F1000Research</i> , 2020, 9, 99.	0.8	2
14	Comparison of major bleeding in patients with acute coronary syndrome that underwent coronary artery bypass grafting treated with clopidogrel or ticagrelor: a systematic review and meta-analysis. <i>F1000Research</i> , 2020, 9, 99.	0.8	1
15	Predictors of COVID-19 severity: a systematic review and meta-analysis. <i>F1000Research</i> , 2020, 9, 1107.	0.8	113
16	Global prevalence and pathogenesis of headache in COVID-19: A systematic review and meta-analysis. <i>F1000Research</i> , 2020, 9, 1316.	0.8	26
17	The Association Between Glutathione S-Transferase P1 105Ile>Val Gene Polymorphism and the Risk of Bladder Cancer: A Meta-Analysis. <i>Turkiye Klinikleri Journal of Medical Sciences</i> , 2020, 40, 250-259.	0.1	4
18	Nitride oxide synthase 3 and klotho gene polymorphisms in the pathogenesis of chronic kidney disease and age-related cognitive impairment: a systematic review and meta-analysis. <i>F1000Research</i> , 2020, 9, 252.	0.8	1

#	ARTICLE	IF	CITATIONS
19	Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis. F1000Research, 0, 10, 64.	0.8	2
20	Seroconversion rates among different designs of COVID-19 vaccines: a network meta-analysis of randomized controlled trials. F1000Research, 0, 11, 299.	0.8	0